Alesta Therapeutics
Latest round
- Series A
Last raised
- Jan 2025
Total raised
- $67M
Investors
- 7
About Alesta Therapeutics
Established in 2021 and based in Leiden, Netherlands, Alesta Therapeutics operates as a biotechnology company that researches and develops small molecules for rare diseases. In August 2026, BioMarin Pharmaceutical Inc. agreed to acquire Alesta Therapeutics from Droia Ventures, Thuja Capital, Frazier Lifesciences Acquisition Corporation, Novartis Venture Fund, RTW Investments, RV Invest, and SSI Strategy Holdings LLC for an upfront payment of USD 275 million and will receive additional payment of approximately USD 215 million upon achieving development and regulatory milestones. The company focuses on the development of innovative oral small molecules intended for the treatment of rare diseases. Their core products include ALE1, addressing hypophosphatasia (HPP), and ALE2, targeting Charcot-Marie-Tooth disease (CMT). ALE1 is designed to treat the full spectrum of HPP symptoms, which can affect bone and dental health, while ALE2 aims to mitigate chronic neurotoxicity associated with specific genetic alterations in CMT. These products are currently in the pre-clinical and clinical development stages, with ALE1 expected to enter clinical studies in 2025.The August 2026 acquisition enables BioMarin Pharmaceutical Inc. to accelerate the development and commercialization of ALE1, an oral small-molecule therapy for hypophosphatasia.
Who invested in Alesta Therapeutics
7 investors across 2 rounds
See all investors in Alesta Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Alesta Therapeutics
Who invested in Alesta Therapeutics?
Alesta Therapeutics has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Alesta Therapeutics raised?
Alesta Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Alesta Therapeutics last raise money?
Alesta Therapeutics's most recent round on record is a Series A, in Jan 2025.
What does Alesta Therapeutics do?
Established in 2021 and based in Leiden, Netherlands, Alesta Therapeutics operates as a biotechnology company that researches and develops small molecules for rare diseases.
Where is Alesta Therapeutics headquartered?
Alesta Therapeutics is headquartered in Leiden, Netherlands.
Which VCs invest in companies like Alesta Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Alesta Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Alesta Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.